On Tuesday, Following Stocks were among the “Top Losers” of U.S. Stock Market: Celladon Corporation, (NASDAQ:CLDN), OvaScience, (NASDAQ:OVAS), Teck Resources, (NYSE:TCK), Peabody Energy, (NYSE:BTU)
Celladon Corporation, (NASDAQ:CLDN), with shares declined -12.60%, closed at $18.94.
OvaScience, (NASDAQ:OVAS), with shares dropped -9.04%, settled at $34.73.
Teck Resources, (NYSE:TCK), with shares dipped -10.09%, and closed at $13.73.
Peabody Energy, (NYSE:BTU), plummeted -7.87%, and closed at $4.92, hitting new 52-week low of $4.76.
Latest NEWS regarding these Stocks are depicted underneath:
Celladon Corporation (NASDAQ:CLDN)
Celladon Corporation (CLDN), declared financial results for the quarter and year ended December 31, 2014 and recent corporate highlights.
Fourth Quarter and Year-End 2014 Financial Results:
- Cash, cash equivalents and investments as of December 31, 2014 were $84.9 million.
- Research and development expenses were $7.2 million and $5.2 million for the fourth quarter of 2014 and 2013, respectively. Research and development expenses were $22.7 million and $16.9 million for the years ended December 31, 2014 and 2013, respectively.
- General and administrative expenses were $3.8 million and $0.8 million for the fourth quarter of 2014 and 2013, respectively. General and administrative expenses were $10.3 million and $3.0 million for the years ended December 31, 2014 and 2013, respectively.
- Other expense, net was $0.4 million and $0.2 million for the fourth quarter of 2014 and 2013, respectively. Other expense was $0.8 million and $0.1 million for the years ended 2014 and 2013, respectively.
- Merged net loss was $11.3 million and $6.2 million for the fourth quarter of 2014 and 2013, respectively. Merged net loss was $33.9 million and $20.1 million for the years ended December 31, 2014 and 2013, respectively. The merged net loss comprised of stock-based compensation of $1.1 million and $0.3 million for the fourth quarter of 2014 and 2013, respectively and $3.3 million and $1.4 million for the years ended December 31, 2014 and 2013, respectively.
Celladon Corporation, a clinical-stage biotechnology corporation, focuses on developing treatments for heart failure, diabetes, and neurodegenerative diseases. The corporation’s lead product candidate comprises MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that results in inadequate pumping of the heart.
OvaScience, Inc. (NASDAQ:OVAS)
OvaScience, Inc. (OVAS), declared that presentations by fertility specialists offering the Corporation’s AUGMENTSM fertility treatment stated encouraging pregnancy rates in women who formerly failed multiple cycles of in vitro fertilization (IVF). Clinical reports from two international IVF clinics will be featured at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting. The AUGMENT treatment is not accessible in the United States.
Robert F. Casper, M.D., F.R.C.S.(C), Medical Director of TCART Fertility Partners of Toronto, Canada, a mitochondrial expert and one of the first IVF specialists to use the AUGMENT treatment in clinical practice, stated initial patient experiences in women whose ages ranged from 28 to 40 years and who had one to three previous failed IVF cycles, often with poor embryo quality. In 26 women who received the AUGMENT treatment, there were 9 clinical pregnancies1 out of 17 embryo transfers (53%).2
The results stated in the poster presentation represent experiences from a small number of patients with different diagnoses, ages and preceding IVF history. As of this reporting, pregnancy rates across IVF clinics that offer the AUGMENT treatment presently range from 25% - 53%, which comprises clinics that are treating some of the more challenging infertility patients. OvaScience is collecting AUGMENT patient experience in a first-of-its-kind international registry, and anticipates sharing information from a broader patient experience when it is accessible.
The AUGMENT treatment is a fertility treatment specifically designed to use the mitochondria, or energy, from a woman’s own egg precursor cells – immature egg cells found inside the protective ovarian lining – to improve egg health.
OvaScience, Inc., a life science corporation, engages in the discovery, development, and commercialization of new treatments for infertility. The corporations patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman’s own ovaries.
Teck Resources Limited (NYSE:TCK)
Teck Resources Limited (TCK), will release its first quarter 2015 earnings results on Tuesday, April 21, 2015 before market open.
The corporation will hold an investor conference call to talk about the first quarter 2015 earnings results at 11:00 a.m. Eastern time / 8:00 a.m. Pacific time on Tuesday, April 21, 2015. The conference call dial-in is 416.340.2216 or toll free 866.223.7781, no pass code required. Media are invited to attend on a listen-only basis.
Teck Resources Limited explores, develops, and produces natural resources in the Americas, the Asia Pacific, Europe, and Africa. Its principal products comprise copper, counting copper concentrates and cathode copper; steelmaking coal; and refined zinc and zinc concentrates.
Peabody Energy Corp. (NYSE:BTU)
Peabody Energy Corp. (BTU), declared that the formerly declared tender offer to purchase for cash any and all of the $650 million aggregate principal amount outstanding of its 7 3/8% Senior Notes due 2016 expired at 11:59 p.m., New York City time, on March 27, 2015.
After the expiration of the early tender period on March 13, 2015, an additional $1,228,000 principal amount of notes were tendered and not validly withdrawn. In total, at the deadline of 11:59 p.m., New York City time, March 27, 2015, $566,879,000 principal amount of all outstanding notes were tendered and not validly withdrawn, representing about 87% of all outstanding notes. The Corporation purchased for cash, on March 16, 2015, $565,651,000 principal amount of notes tendered and not validly withdrawn during the early tender period. The Corporation anticipates to make payment on all notes tendered after the expiration of the early tender period recently and holders of such notes will receive the tender offer consideration of $1,072.71 per $1,000 principal amount together with accrued and unpaid interest on such notes from the last interest payment date to, but not counting, March 30, 2015. The Corporation will redeem on April 15, 2015 any outstanding notes following a redemption notice delivered on March 16, 2015.
BofA Merrill Lynch and Morgan Stanley acted as the dealer managers for the tender offer. Global Bondholder Services Corporation acted as the information agent for the tender offer.
Peabody Energy Corporation engages in the mining of coal. The corporation operates through Western U.S. Mining, Midwestern U.S. Mining, Australian Mining, Trading and Brokerage, and Corporate and Other segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
